Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived… (NCT07444632) | Clinical Trial Compass
Not Yet RecruitingPhase 1
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
United States60 participantsStarted 2026-08-31
Plain-language summary
This is a phase 1 basket trial of TGFBR2 KO CAR27/IL-15 NK cells after lymphodepleting chemotherapy for patients with R/R B-NHL, HL, T-NHL or B-ALL.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18-75 years of age.
✓. Diagnosis of relapsed B-NHL, HL, T-NHL, or B-ALL in refractory relapse, defined as:
✓. Expression of CD70 in the pre-enrollment sample \>/= 20% measured by immunohistochemistry or flow cytometry.
✓. Measurable disease, defined by \>/= 1 histologically confirmed hypermetabolic lesion on PET/CT scan.
✓. ALT and/or AST ≤ 3 x ULN, and bilirubin and ALP ≤ 2 x ULN.
Exclusion criteria
✕8. Ability to understand and willingness to sign a written informed document.
✕9. Agree to sign consent to the long-term follow-up protocol PA17-0483 to fulfill the institutional responsibilities to various regulatory agencies.
✕. Lymphoma or ALL in CR with no measurable sites of disease.
✕. Major surgery \<4 weeks prior to first dose of study drug.
✕. Any other severe or uncontrolled disease or condition which mightincrease the risk associated with study participation.
What they're measuring
1
Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year
✕. Any other malignancy known to be active, with the exception of treated cervical intraepithelial neoplasia and non-melanoma skincancer.
✕. Grade \>/= 3 non-hematologic toxicity from prior therapy that has notimproved to grade \</= 2.
✕. Active hepatitis B, either active carrier (HBsAg +) or viremic (HBV DNA \>/=10,000 copies/mL, or \>/=2,000 IU/mL), or hepatitis C (detectable viral load by HCV RNA PCR).